Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 10/20 | 0.39 |
| ▸ | HTR2C | P28335 | 10/20 | 0.39 |
| ▸ | NCF1 | P14598 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8442130 | 0.78 | HTR2A (0.41) | HTR2AHTR2CNCF1L3MBTL1MEN1 | |
| SCHEMBL46703 | 0.78 | L3MBTL3 (0.42) | HTR2AHTR2CNCF1L3MBTL1MEN1 | |
| SCHEMBL2152599 | 0.76 | — | — | |
| SCHEMBL17888490 | 0.76 | HTR2A (0.40) | HTR2AHTR2CNCF1L3MBTL1MEN1 | |
| SCHEMBL20614488 | 0.75 | NCF1 (0.42) | HTR2AHTR2CNCF1L3MBTL1MEN1 | |
| SCHEMBL14417472 | 0.74 | NCF1 (0.42) | HTR2AHTR2CNCF1L3MBTL1MEN1 | |
| SCHEMBL22302062 | 0.74 | HTR2A (0.39) | HTR2AHTR2CNCF1L3MBTL1MEN1 | |
| SCHEMBL20045403 | 0.74 | HTR2A (0.41) | HTR2AHTR2CNCF1L3MBTL1MEN1 | |
| SCHEMBL14422014 | 0.74 | HTR2A (0.44) | HTR2AHTR2CL3MBTL1MEN1KMT2A | |
| SCHEMBL17072006 | 0.74 | HTR2A (0.41) | HTR2AHTR2CNCF1L3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023083373-A1 | COMPOUND USED AS SRC INHIBITOR | 微境生物医药科技(上海)有限公司 | 2023-05-19 | — | — | WO | disclosed |
| WO-2020259724-A2 | PYRAZOLONE AND PYRIMIDINE COMPOUND, AND PREPARATION METHOD AND USE THEREFOR | 上海医药集团股份有限公司 | 2020-12-30 | — | — | WO | disclosed |
| US-10577384-B2 | Substituted asymmetric ureas as modulators of ghrelin receptor activity | HELSINN HEALTHCARE SA (CH) | 2020-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10577384-B2 | Substituted asymmetric ureas as modulators of ghrelin receptor activity | GHSR, GIPR, UTS2R | HTR2A 414/4885HTR2C 464/4885NCF1 1363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.